(Q36488752)

14 August 2017

1 reference

title

Mechanisms of drug inhibition of signalling molecules (English)

1 reference

14 August 2017

Judith S Sebolt-Leopold

series ordinal

1

1 reference

14 August 2017

Jessie M English

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 May 2006

1 reference

14 August 2017

1 reference

14 August 2017

441

1 reference

14 August 2017

457-462

1 reference

14 August 2017

7092

1 reference

https://scigraph.springernature.com/pub.10.1038/nature04874

14 August 2017

0 references

cites work

Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Identification of a transformation-specific antigen induced by an avian sarcoma virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Protein kinase activity associated with the avian sarcoma virus src gene product

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Evidence that the transforming gene of avian sarcoma virus encodes a protein kinase associated with a phosphoprotein

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Oncogenic kinase signalling

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Critical update and emerging trends in epidermal growth factor receptor targeting in cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Lessons from phase III clinical trials on anti-VEGF therapy for cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Acquisition of sensitivity of stress-activated protein kinases to the p38 inhibitor, SB 203580, by alteration of one or more amino acids within the ATP binding pocket.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Structural basis of inhibitor selectivity in MAP kinases

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

The protein kinase complement of the human genome

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

A synthetic inhibitor of the mitogen-activated protein kinase cascade

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Identification of a novel inhibitor of mitogen-activated protein kinase kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

The specificities of protein kinase inhibitors: an update

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Structures of human MAP kinase kinase 1 (MEK1) and MEK2 describe novel noncompetitive kinase inhibition.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

High affinity targets of protein kinase inhibitors have similar residues at the positions energetically important for binding

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

21 January 2018

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

21 January 2018

Role of FLT3 in leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Discovery of a novel Raf kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

BAY 43-9006: preclinical data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Anti-erbB-2 antibody trastuzumab in the treatment of HER2-amplified breast cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Targeting angiogenesis in cancer: clinical development of bevacizumab

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

FDA drug approval summary: gefitinib (ZD1839) (Iressa) tablets

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Approval summary for erlotinib for treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of at least one prior chemotherapy regimen

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Lapatinib: a novel dual tyrosine kinase inhibitor with activity in solid tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Mutations of the BRAF gene in human cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

BRAF mutation predicts sensitivity to MEK inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Targeting the mitogen-activated protein kinase cascade to treat cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Progress towards therapeutic small molecule MEK inhibitors for use in cancer therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

A new mutation in the KIT ATP pocket causes acquired resistance to imatinib in a gastrointestinal stromal tumor patient

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Targeted CML therapy: controlling drug resistance, seeking cure

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Allosteric inhibitors of Bcr-abl-dependent cell proliferation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

A role for K-ras in conferring resistance to the MEK inhibitor, CI-1040.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lun

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Treatment of metastatic renal cell carcinoma with a combination of bevacizumab and erlotinib.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

21 January 2018

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Activation mechanism of the MAP kinase ERK2 by dual phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Activation loop phosphorylation and catalysis in protein kinases: is there functional evidence for the autoinhibitor model?

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

Signatures guide drug choice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNATURE04874

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NATURE04874

1 reference

Dimensions Publication ID

14 August 2017

0 references

1 reference